NI200900219A - DERIVADOS DE BENCIMIDAZOL Caso: PC 33611A - Google Patents

DERIVADOS DE BENCIMIDAZOL Caso: PC 33611A

Info

Publication number
NI200900219A
NI200900219A NI200900219A NI200900219A NI200900219A NI 200900219 A NI200900219 A NI 200900219A NI 200900219 A NI200900219 A NI 200900219A NI 200900219 A NI200900219 A NI 200900219A NI 200900219 A NI200900219 A NI 200900219A
Authority
NI
Nicaragua
Prior art keywords
benzimidazole derivatives
case
mammals
compounds
relates
Prior art date
Application number
NI200900219A
Other languages
English (en)
Inventor
Scott Jones Christopher
La Greca Susan
Li Qifang
John Munchhof Michael
Alan Reiter Lawrence
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NI200900219A publication Critical patent/NI200900219A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto de fórmula I o una sal farmacéuticamente aceptable del mismo, en la que R1, R2, R3A, R3B, R4, R5, X, m y n son como se definen en el presente documento. Tales derivados de bencimidazol novedosos son útiles en el tratamiento celular anormal, tal como cáncer, en mamíferos. La presente invención también se refiere a un procedimiento de uso de tales compuestos en el tratamiento de crecimiento celular anormal en mamíferos, especialmente seres humanos , y a composiciones farmacéuticas que contienen tales compuestos.
NI200900219A 2007-06-29 2009-12-18 DERIVADOS DE BENCIMIDAZOL Caso: PC 33611A NI200900219A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94728707P 2007-06-29 2007-06-29
US4164508P 2008-04-02 2008-04-02

Publications (1)

Publication Number Publication Date
NI200900219A true NI200900219A (es) 2010-03-11

Family

ID=40161351

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900219A NI200900219A (es) 2007-06-29 2009-12-18 DERIVADOS DE BENCIMIDAZOL Caso: PC 33611A

Country Status (46)

Country Link
US (2) US8148401B2 (es)
EP (1) EP2170860B9 (es)
JP (2) JP4567099B2 (es)
KR (1) KR101143246B1 (es)
CN (1) CN101687841B (es)
AP (1) AP2377A (es)
AR (1) AR067346A1 (es)
AU (1) AU2008272641B2 (es)
BR (1) BRPI0813412B8 (es)
CA (1) CA2690953C (es)
CL (1) CL2008001922A1 (es)
CO (1) CO6160232A2 (es)
CR (1) CR11150A (es)
CU (1) CU23847B1 (es)
CY (2) CY1118650T1 (es)
DK (1) DK2170860T5 (es)
DO (1) DOP2009000278A (es)
EA (1) EA016888B1 (es)
EC (1) ECSP099803A (es)
ES (1) ES2609258T3 (es)
FR (1) FR20C1038I2 (es)
GE (1) GEP20125702B (es)
GT (1) GT200900328A (es)
HK (1) HK1139658A1 (es)
HN (1) HN2008000974A (es)
HR (1) HRP20161562T2 (es)
HU (2) HUE030052T4 (es)
IL (1) IL202420A (es)
LT (2) LT2170860T (es)
MA (1) MA31466B1 (es)
ME (1) ME00962B (es)
MY (1) MY148636A (es)
NI (1) NI200900219A (es)
NL (1) NL301057I2 (es)
NO (1) NO2020027I1 (es)
NZ (1) NZ581889A (es)
PA (1) PA8785401A1 (es)
PE (2) PE20121010A1 (es)
PL (1) PL2170860T3 (es)
PT (1) PT2170860T (es)
RS (1) RS55395B9 (es)
SI (1) SI2170860T1 (es)
TN (1) TN2009000544A1 (es)
TW (1) TWI371451B (es)
UY (1) UY31164A1 (es)
WO (1) WO2009004427A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2170860T1 (sl) 2007-06-29 2017-01-31 Pfizer Inc. Benzimidazolni derivati
WO2010028192A1 (en) 2008-09-03 2010-03-11 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
KR20120026534A (ko) * 2009-06-11 2012-03-19 시에나 바이오테크 에스.피.에이. 헤지호그 경로 길항제 및 그의 치료적 적용
BR112012004134A2 (pt) 2009-08-26 2017-06-20 Takeda Pharmaceuticals Co "composto derivado dee anel heterocíclico fundido, pró-droga, medicamento, e , uso do composto ou sal ou uma pró-droga do mesmo"
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
CA2813162C (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2- derivatives as smoothened receptor modulators
JP5452459B2 (ja) 2010-12-16 2014-03-26 株式会社Nttドコモ ホーム基地局及びハンドオーバ方法
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2012122370A2 (en) * 2011-03-08 2012-09-13 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
AU2012314943B9 (en) 2011-09-26 2017-06-08 Merck Patent Gmbh Benzyl piperidine compounds as lysophosphatidic acid (LPA) receptor antagonist
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
WO2014143666A1 (en) 2013-03-15 2014-09-18 Biomarin Pharmaceutical Inc. Hdac inhibitors
US10435364B2 (en) 2013-04-17 2019-10-08 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
EP3063302B1 (en) 2013-10-30 2019-12-04 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
EP3666768B1 (en) * 2015-04-24 2022-06-15 Pfizer Inc. Preparation process of a crystalline form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate; a crystalline form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea imidazole complex (1:1)
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2020164722A (ja) * 2019-03-29 2020-10-08 デクセリアルズ株式会社 接着剤組成物
WO2021154901A1 (en) 2020-01-28 2021-08-05 Teva Pharmaceuticals International Gmbh Processes for the preparation of glasdegib and salt thereof and solid state forms of glasdegib maleate and process for preparation thereof
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
EP4126237B1 (en) 2020-03-26 2024-04-10 LEK Pharmaceuticals d.d. Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
JP7327855B2 (ja) 2020-06-26 2023-08-16 ラクオリア創薬株式会社 レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ530580A (en) 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
SI1499607T1 (sl) 2001-12-04 2006-06-30 Actelion Pharmaceuticals Ltd 4-(piperidil- in pirolidil-alkil-ureido)-kinolinikot antagonisti receptorja urotensina II
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2004035549A1 (en) 2002-10-17 2004-04-29 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
WO2005042495A1 (en) 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity
RU2006118312A (ru) 2003-10-28 2007-12-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бензимидазолы, полезные в качестве модуляторов ионных каналов
CA2587489C (en) * 2004-11-03 2013-12-31 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE102005012875B4 (de) 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
WO2008064830A1 (en) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their pharmaceutical uses
JP2010513263A (ja) 2006-12-15 2010-04-30 ファイザー・プロダクツ・インク ベンズイミダゾール誘導体
SI2170860T1 (sl) 2007-06-29 2017-01-31 Pfizer Inc. Benzimidazolni derivati
WO2009154739A2 (en) 2008-06-17 2009-12-23 Duke University Smoothened receptor modulators
JP5555236B2 (ja) 2008-08-25 2014-07-23 アイアールエム・リミテッド・ライアビリティ・カンパニー ヘッジホッグ経路モジュレーター

Also Published As

Publication number Publication date
CY1118650T1 (el) 2017-07-12
US8148401B2 (en) 2012-04-03
AU2008272641B2 (en) 2013-08-29
CO6160232A2 (es) 2010-05-20
GEP20125702B (en) 2012-12-10
IL202420A (en) 2014-05-28
JP2010531869A (ja) 2010-09-30
BRPI0813412A2 (pt) 2014-12-30
LTC2170860I2 (lt) 2022-03-10
MY148636A (en) 2013-05-15
AP2009005089A0 (en) 2009-12-31
HRP20161562T2 (hr) 2017-04-21
CU23847B1 (es) 2012-10-15
MA31466B1 (fr) 2010-06-01
CY2020028I1 (el) 2020-11-25
RS55395B9 (sr) 2020-01-31
PT2170860T (pt) 2017-01-04
CA2690953C (en) 2012-10-02
NZ581889A (en) 2011-05-27
EA016888B1 (ru) 2012-08-30
AR067346A1 (es) 2009-10-07
SI2170860T1 (sl) 2017-01-31
TWI371451B (en) 2012-09-01
CL2008001922A1 (es) 2009-01-02
US20090005416A1 (en) 2009-01-01
JP4567099B2 (ja) 2010-10-20
PE20090772A1 (es) 2009-06-24
PA8785401A1 (es) 2009-01-23
NL301057I1 (nl) 2020-07-22
KR101143246B1 (ko) 2012-05-18
CN101687841A (zh) 2010-03-31
NO2020027I1 (no) 2020-08-11
LT2170860T (lt) 2017-01-10
CN101687841B (zh) 2013-07-10
EA200971104A1 (ru) 2010-06-30
ES2609258T3 (es) 2017-04-19
HK1139658A1 (en) 2010-09-24
BRPI0813412B8 (pt) 2021-05-25
EP2170860A2 (en) 2010-04-07
US20120157495A1 (en) 2012-06-21
WO2009004427A3 (en) 2009-06-04
EP2170860B1 (en) 2016-11-02
FR20C1038I2 (fr) 2021-08-13
TW200911792A (en) 2009-03-16
HUS2000031I1 (hu) 2020-09-28
IL202420A0 (en) 2010-06-30
CY2020028I2 (el) 2020-11-25
LTPA2020528I1 (lt) 2020-09-25
AU2008272641A1 (en) 2009-01-08
DK2170860T5 (en) 2017-03-20
CU20090225A7 (es) 2012-02-15
CA2690953A1 (en) 2009-01-08
ECSP099803A (es) 2010-01-29
DOP2009000278A (es) 2009-12-31
DK2170860T3 (en) 2017-01-09
TN2009000544A1 (fr) 2011-03-31
CR11150A (es) 2010-02-08
HN2008000974A (es) 2011-01-24
UY31164A1 (es) 2009-01-30
WO2009004427A2 (en) 2009-01-08
NL301057I2 (nl) 2020-09-10
EP2170860B9 (en) 2017-02-22
US8431597B2 (en) 2013-04-30
GT200900328A (es) 2011-08-29
JP2010280693A (ja) 2010-12-16
PL2170860T3 (pl) 2017-05-31
BRPI0813412B1 (pt) 2020-01-21
KR20100028120A (ko) 2010-03-11
ME00962B (me) 2012-06-20
HUE030052T4 (en) 2017-06-28
RS55395B1 (sr) 2017-04-28
HRP20161562T1 (hr) 2016-12-30
AP2377A (en) 2012-03-07
PE20121010A1 (es) 2012-08-06
HUE030052T2 (hu) 2017-04-28
FR20C1038I1 (es) 2020-10-02

Similar Documents

Publication Publication Date Title
NI200900219A (es) DERIVADOS DE BENCIMIDAZOL Caso: PC 33611A
EA200901250A1 (ru) Сульфониламидные производные для лечения аномального роста клеток
SV2011003853A (es) Compuestos organicos
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
GEP20125487B (en) Organic compounds and their use
CO6630154A2 (es) Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
ECSP088871A (es) Derivados de triazolopirazina
CR20120296A (es) Nuevos compuestos de espiropiperidina
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
CR10199A (es) Derivados de benzimidazol
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
DOP2009000214A (es) Macrolidos basados en eritromicina
UA93313C2 (en) Benzimidazole derivatives
DOP2007000096A (es) Derivados de triazolopirazina
CU20080126A7 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CU23681B7 (es) Derivados de triazolopirazina
CU20140033A7 (es) Derivados de pirrolopirimidina y purina
NI200500205A (es) "derivados de pirimidina para el tratamiento del crecimiento celular anorma."